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As we enter an era of precision medicine and targeted therapies in the treatment of 
metastatic cancer, we face new challenges for both patients and providers alike as we establish 
clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is 
the fact that patients with advanced cancer may have disproportionate expectations of personal 
benefit when participating in clinical trials designed to generate generalizable knowledge. Patient 
and physician goals of treatment may not align, and reconciliation of their disparate perceptions 
must be addressed. However, it is particularly challenging to manage a patient’s expectations 
when the goal of precision medicine – personalized response – exacerbates our inability to 
predict outcomes for any individual patient. The precision medicine informed consent process 
must therefore directly address this issue. We are challenged to honestly, clearly, and 
compassionately engage a patient population in an informed consent process that is responsive to 
their vulnerability, as well as ever-evolving indications and evidence. This era requires a 
continual reassessment of expectations and goals from both sides of the bed.  












 As we enter an era of precision oncology, genomic characterization is playing an 
increasingly larger role in individualized treatment.1-3 However, precision oncology research 
challenges existing research guidelines and regulations. The very nature of such “basket” or 
“registration” trials defies current norms of standardization. Despite overwhelming enthusiasm, 
few enrolled patients have benefitted from involvement in these early efforts.4 
A multi-disciplinary approach is necessary to convey to prospective subjects the 
complexity involved in participating in a precision medicine trial.  Participants in clinical trials 
are often challenged by misapprehensions that the purpose of clinical research is to gain 
generalizable knowledge regardless of whether the individual will benefit from the intervention 
of the trial.5 With the rapid growth of an exciting field comes new challenges for patients and 
providers alike in considering this concept.  
Contextualizing Goals  
Patients with advanced cancer have disproportionate expectations of the probability of 
personal benefit when consenting to new therapies, such as precision oncology. This disconnect 
may influence their decision. Weeks et al showed the majority of patients with stage IV lung and 
colon cancer did not recognize that their treatment regimen was unlikely to lead to a cure.6 This 
alarming result calls into question the effectiveness of our informed consent process, as well as 
our patients’ intense vulnerability and potentially misplaced optimism.7  
This complex area of informed consent is magnified in precision oncology trials in which 
neither outcomes nor toxicities are well-characterized.  The individualized nature of precision 
medicine protocols, in which treatment is driven by personalized data interpretation, is more 
evocative of traditional clinical care—confounding careful delineation of the clinical and 










research spheres. At this intersection, the distinction between a “patient” and a “subject” 
becomes obscured. Thus, we must not only ensure that our current patients are fully informed 
about their personal therapeutic options but also reconcile our desire to obtain data integral to 
advancing cancer therapeutics for future patients. 
 Clinicians must be cognizant of patients’ goals of care when discussing precision 
oncology trials. For patients, the goals that motivate enrollment in a precision oncology trial may 
include extending life, reducing symptoms, avoiding toxicities associated with therapy, or cure.  
Patients may also recognize an intrinsic altruistic motivation, but this is often secondary to the 
hope for personal benefit.8  This dichotomy is present in all clinical research, but the uniquely 
personalized nature of precision trials coupled with the vulnerability of subjects with few 
therapeutic options make this more difficult to reconcile. There is currently a dearth of data 
exploring these themes in precision oncology, although empiric studies are ongoing.9 In 
response, the National Cancer Institute has elicited information regarding gaps, opportunities, 
collaborations and areas of outreach in bioethics and cancer research.10   
As providers, we must reconcile and make explicit to patients our goals to obtain data 
integral to advancing cancer therapeutics for future patients, with the personal impact current 
patients experience. Currently, the majority of precision trials remain are early phase, focused 
more on feasibility, dosing, and toxicity.11-14  Thus, clinicians must explain the difference 
between preliminary trial design and later phases relying on existing experimental data.  This 
distinction is especially challenging for patients in the setting of precision oncology due at least 
in part to the rapid incorporation of new research data into clinical therapy. The incorporation of 
seamless drug development strategies may circumvent traditional trial phases by adding 
additional cohorts to promising ongoing trials, further obfuscating how to frame expectations.8,15  










Expectations and Consent 
 During the consent process for these trials, it can be challenging to manage expectations 
when the goal of precision medicine – personalized response – limits our ability to predict 
outcomes for any given patient.  It has been such an obstacle that the field has replaced the term 
“personalized medicine” with “precision medicine”: a characterization of the genetic risk and 
targeted therapeutic options for subpopulations rather than for subjects/patients themselves.16 
While “exceptional responders” have been identified and frequently publicized, these patients 
still represent the elusive outcome.14 As such, much of the informed consent process requires 
assessing potential participants’ expectations of cure and tempering them considerably.  
It seems that in spite of our most honest disclosure of facts, a patient’s choice to become 
a subject is likely to represent optimism rather than altruism.17 The empiric literature 
demonstrates that the therapeutic misconception is more complex than subjects simply 
misunderstanding intent, and instead reflects patient’s innate beliefs and hopes irrespective of 
statistics.18  Nevertheless, potential exploitation is problematic. Given the inherent nature of 
precision medicine trials, how do we extrapolate one patient’s outcomes (the N=1 dilemma) 
when counseling subjects? Of particular concern with advanced disease, enrolling in a precision 
medicine research protocol may exhaust precious time without guarantee, not only of outcome, 
but even of a therapeutic option. In addition to the potential toxicities and unknown benefit from 
novel targeted agents, delaying cancer-directed therapy may lead to unwarranted harm. 
Emerging data reiterates the downstream toxicities of such therapies that may persist, including 
formidable autoimmune consequences of immunotherapy.  
While largely beyond our scope, tumor sequencing performed off-trial eliminates 
conflicting research versus clinical goals, but may engender formidable out-of-pocket expenses 










compounding unrealistic expectations.19 Many patients facing metastatic cancer are best served 
by palliative care and foregoing further cancer-directed therapy.  But the unmet promise of 
precision oncology and other advances such as cancer immunotherapy may convince patients 
that a new drug or trial is a better bet.20 Our job as clinicians and researchers is not to dissuade or 
de-emphasize trials or cancer-directed therapies, but rather to select potential subjects based 
primarily upon their own best interests, preferences, and reflective of their intense vulnerability.  
In many cases, acceptance of supportive care alone is indeed the appropriate choice.  
Ultimately, potential subjects and patients should be counseled that in most cases, the use 
of genomics to identify personalized actionable targets is still in the exploratory phase of clinical 
research, and that precision medicine’s benefit remains elusive. How the regulatory environment 
will evolve with the science also remains to be seen. Empirical studies are needed to explore and 
reframe patient expectations for benefit from precision oncology trials and clinical care. We are 
challenged to honestly, clearly, and compassionately engage a patient population in a challenging 
informed consent process that reflects their vulnerability, as well as ever-evolving evidence.  
This new era requires a continual reassessment of expectations and goals from both sides of the 
bed. 
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